🚀 VC round data is live in beta, check it out!
Biosergen Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biosergen and similar public comparables like ExpreS2ion Biotech, Guard Therapeutics, CASI Pharmaceuticals, HCW Biologics and more.
Biosergen Overview
About Biosergen
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen’ s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
Founded
2021
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$911K
Biosergen Financials
Biosergen reported last fiscal year revenue of — and negative EBITDA of ($4M).
In the same fiscal year, Biosergen generated — in gross profit, ($4M) in EBITDA losses, and had net loss of ($4M).
Biosergen P&L
In the most recent fiscal year, Biosergen reported revenue of — and EBITDA of ($4M).
Biosergen expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biosergen Stock Performance
Biosergen has current market cap of $3M, and enterprise value of $911K.
Market Cap Evolution
Biosergen's stock price is $1.10.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $911K | $3M | 0.3% | XXX | XXX | XXX | $-1.90 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiosergen Valuation Multiples
Biosergen trades at (0.2x) EV/EBITDA.
Biosergen Financial Valuation Multiples
As of April 19, 2026, Biosergen has market cap of $3M and EV of $911K.
Equity research analysts estimate Biosergen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biosergen has a P/E ratio of (0.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3M | XXX | $3M | XXX | XXX | XXX |
| EV (current) | $911K | XXX | $911K | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.2x) | XXX | XXX | XXX |
| P/E | — | XXX | (0.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biosergen Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biosergen Margins & Growth Rates
Biosergen's revenue in the last fiscal year grew by —.
Biosergen's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.2M for the same period.
Biosergen Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 114% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biosergen Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biosergen | XXX | XXX | XXX | XXX | XXX | XXX |
| ExpreS2ion Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Guard Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| CASI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| HCW Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Gabather | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biosergen M&A Activity
Biosergen acquired XXX companies to date.
Last acquisition by Biosergen was on XXXXXXXX, XXXXX. Biosergen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biosergen
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiosergen Investment Activity
Biosergen invested in XXX companies to date.
Biosergen made its latest investment on XXXXXXXX, XXXXX. Biosergen invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biosergen
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biosergen
| When was Biosergen founded? | Biosergen was founded in 2021. |
| Where is Biosergen headquartered? | Biosergen is headquartered in Sweden. |
| How many employees does Biosergen have? | As of today, Biosergen has over 2 employees. |
| Is Biosergen publicly listed? | Yes, Biosergen is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Biosergen? | Biosergen trades under BIOSGN ticker. |
| When did Biosergen go public? | Biosergen went public in 2021. |
| Who are competitors of Biosergen? | Biosergen main competitors are ExpreS2ion Biotech, Guard Therapeutics, CASI Pharmaceuticals, HCW Biologics. |
| What is the current market cap of Biosergen? | Biosergen's current market cap is $3M. |
| Is Biosergen profitable? | No, Biosergen is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.